Clinical Trial Search

Primary: The Incidence and Severity of Adverse Events in Each Treatment Group in the Double-blind Treatment Period up to 42 Days Post-vaccination. — 13; 13; 2; 22 participants

Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) — 48.9; 40.0…

Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters

Primary: Percentage of Wound Surface Area Change From Baseline to Week 8 — -63; -8.1 percentage of wound surface area

Primary: Median Time (Minutes) After Administration of Intranasal Midazolam Until Patient Achieves Minimal Sedation — 4.7; 4.3; 5.2 minutes

Primary: Reduction of Menstrual Bleeding to Normal or Below Normal at 12 Months — 95; 41 participants

Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL

Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants

Primary: Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks — -12.57; -8.90 mmHg — p=0.010

Primary: Number of Participants With 2-hour Pain Free Active Study Drug — 35; 23; 21; 24 Participants — p=0.0038

Primary: Comfort - First Intervention — 9.3; 9.3; 9.4; 9.3 units on a scale

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 — 563; 747 ng*h/mL

Primary: Number of Participants Experiencing Adverse Events (AEs) — 5; 3; 4; 5 participants

Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants